Blood circulates continuously, carrying cells suspended in plasma. Plasma expanders increase plasma volume by drawing water into circulation. They are used to treat blood loss from hemorrhage, wounds, or surgery. The two main types are crystalloids like saline and colloids like albumin and dextran. Plasma expanders work by increasing osmotic pressure to expand volume. Human albumin is obtained from blood and does not require matching blood type. Dextran is produced by bacteria and acts for 24 hours but can interfere with coagulation.
Introduction.
Causes of Erectile dysfunction
Drugs used for Erectile dysfunction
Mechanism of action .
Structure
Adverse Drug Reactions .
Uses.
Reference
Introduction.
Classification .
Drugs used in Coagulant and Anticoagulant Agents
Mechanism of action .
Structure
Synthesis
Adverse Drug Reactions .
Uses.
Reference
Pharmaceutical Aerosols: Definition, propellants, containers, valves, types of aerosol systems; formulation and manufacture of aerosols; Evaluation of aerosols; Quality control and stability studies
coagulants in detail with all drugs, mechanism of action, advantages, adverse effect, contraindication with example and pictures.
in simplified manner , easy to understand
Dr. Jibachha Sah,M.V.Sc( Veterinary pharmacology, TU,Nepal),posted lecturer notes on AUTONOMIC AND SYSTEMIC PHARMACOLOGY for B.V.Sc & A.H. 6 th semester veterinary students of College of veterinary science,Nepal Polytechnique Institute, Bharatpur, Bhojard, Chitwan, Nepal.I hope this lecture notes may be beneficial for other Nepalese veterinary students. Please send your comment and suggestion .Email:jibachhashah@gmail.com,moble,00977-9845024121
Introduction.
Causes of Erectile dysfunction
Drugs used for Erectile dysfunction
Mechanism of action .
Structure
Adverse Drug Reactions .
Uses.
Reference
Introduction.
Classification .
Drugs used in Coagulant and Anticoagulant Agents
Mechanism of action .
Structure
Synthesis
Adverse Drug Reactions .
Uses.
Reference
Pharmaceutical Aerosols: Definition, propellants, containers, valves, types of aerosol systems; formulation and manufacture of aerosols; Evaluation of aerosols; Quality control and stability studies
coagulants in detail with all drugs, mechanism of action, advantages, adverse effect, contraindication with example and pictures.
in simplified manner , easy to understand
Dr. Jibachha Sah,M.V.Sc( Veterinary pharmacology, TU,Nepal),posted lecturer notes on AUTONOMIC AND SYSTEMIC PHARMACOLOGY for B.V.Sc & A.H. 6 th semester veterinary students of College of veterinary science,Nepal Polytechnique Institute, Bharatpur, Bhojard, Chitwan, Nepal.I hope this lecture notes may be beneficial for other Nepalese veterinary students. Please send your comment and suggestion .Email:jibachhashah@gmail.com,moble,00977-9845024121
This slide share includes definition,indications,dehydration status,types of fluids,when to administer which fluid,how to calculate the fluid to be administered and how to monitor fluid therapy.Hope its helpful.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
The increased availability of biomedical data, particularly in the public domain, offers the opportunity to better understand human health and to develop effective therapeutics for a wide range of unmet medical needs. However, data scientists remain stymied by the fact that data remain hard to find and to productively reuse because data and their metadata i) are wholly inaccessible, ii) are in non-standard or incompatible representations, iii) do not conform to community standards, and iv) have unclear or highly restricted terms and conditions that preclude legitimate reuse. These limitations require a rethink on data can be made machine and AI-ready - the key motivation behind the FAIR Guiding Principles. Concurrently, while recent efforts have explored the use of deep learning to fuse disparate data into predictive models for a wide range of biomedical applications, these models often fail even when the correct answer is already known, and fail to explain individual predictions in terms that data scientists can appreciate. These limitations suggest that new methods to produce practical artificial intelligence are still needed.
In this talk, I will discuss our work in (1) building an integrative knowledge infrastructure to prepare FAIR and "AI-ready" data and services along with (2) neurosymbolic AI methods to improve the quality of predictions and to generate plausible explanations. Attention is given to standards, platforms, and methods to wrangle knowledge into simple, but effective semantic and latent representations, and to make these available into standards-compliant and discoverable interfaces that can be used in model building, validation, and explanation. Our work, and those of others in the field, creates a baseline for building trustworthy and easy to deploy AI models in biomedicine.
Bio
Dr. Michel Dumontier is the Distinguished Professor of Data Science at Maastricht University, founder and executive director of the Institute of Data Science, and co-founder of the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. His research explores socio-technological approaches for responsible discovery science, which includes collaborative multi-modal knowledge graphs, privacy-preserving distributed data mining, and AI methods for drug discovery and personalized medicine. His work is supported through the Dutch National Research Agenda, the Netherlands Organisation for Scientific Research, Horizon Europe, the European Open Science Cloud, the US National Institutes of Health, and a Marie-Curie Innovative Training Network. He is the editor-in-chief for the journal Data Science and is internationally recognized for his contributions in bioinformatics, biomedical informatics, and semantic technologies including ontologies and linked data.
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Cancer cell metabolism: special Reference to Lactate PathwayAADYARAJPANDEY1
Normal Cell Metabolism:
Cellular respiration describes the series of steps that cells use to break down sugar and other chemicals to get the energy we need to function.
Energy is stored in the bonds of glucose and when glucose is broken down, much of that energy is released.
Cell utilize energy in the form of ATP.
The first step of respiration is called glycolysis. In a series of steps, glycolysis breaks glucose into two smaller molecules - a chemical called pyruvate. A small amount of ATP is formed during this process.
Most healthy cells continue the breakdown in a second process, called the Kreb's cycle. The Kreb's cycle allows cells to “burn” the pyruvates made in glycolysis to get more ATP.
The last step in the breakdown of glucose is called oxidative phosphorylation (Ox-Phos).
It takes place in specialized cell structures called mitochondria. This process produces a large amount of ATP. Importantly, cells need oxygen to complete oxidative phosphorylation.
If a cell completes only glycolysis, only 2 molecules of ATP are made per glucose. However, if the cell completes the entire respiration process (glycolysis - Kreb's - oxidative phosphorylation), about 36 molecules of ATP are created, giving it much more energy to use.
IN CANCER CELL:
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
Unlike healthy cells that "burn" the entire molecule of sugar to capture a large amount of energy as ATP, cancer cells are wasteful.
Cancer cells only partially break down sugar molecules. They overuse the first step of respiration, glycolysis. They frequently do not complete the second step, oxidative phosphorylation.
This results in only 2 molecules of ATP per each glucose molecule instead of the 36 or so ATPs healthy cells gain. As a result, cancer cells need to use a lot more sugar molecules to get enough energy to survive.
introduction to WARBERG PHENOMENA:
WARBURG EFFECT Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside.
Otto Heinrich Warburg (; 8 October 1883 – 1 August 1970) In 1931 was awarded the Nobel Prize in Physiology for his "discovery of the nature and mode of action of the respiratory enzyme.
WARNBURG EFFECT : cancer cells under aerobic (well-oxygenated) conditions to metabolize glucose to lactate (aerobic glycolysis) is known as the Warburg effect. Warburg made the observation that tumor slices consume glucose and secrete lactate at a higher rate than normal tissues.
2. Blood:-
Blood is a fluid connective tissue that
circulates continuously around the body,
allowing constant communication between
tissues distant from each other.
Plasma:-
A clear , straw coloured , watery fluid in
which several different types of blood cells
are suspended.
3. Blood and Plasma volume expander’s
-Plasma expanders are agents that have
relatively high molecular weight and boost
the plasma volume by increasing the osmotic
pressure.
-They are used to treat patient’s who have
suffered hemorrhage , have severe wound ,
have blood loss ,etc.
-Volume expanders are the intravenous fluid
solution that are used to increased or retain
the volume of fluid in the circulating Blood.
4. -these are also used to replace fluid that are
lost due to illness , trauma or surgery or used
to correct hypovolemia due to loss of blood
or plasma.
5. Types of Volume Expanders :-
There are two main types of volume
expanders:-
1- Crystalloids :- Crystalloids are aqueous
solution of normal saline, dextrose,etc.
2- Colloids :- Colloids are larger insoluble
molecules ; such as dextrin, human albumin,
Blood .
6. Generally used Plasma Expanders:-
>Human albumin.
>Dextran.
>Degraded gelatin polymer [Polygeline]
>Hydroxyethyl starch.
>Polyvinyl Pyrrolidone.[pvp]
7. Mechanism of action :-
>Generally works on the principle of osmosis.
>Increased Plasma osmotic pressure, drawing
water into plasma from intestinal fluid.
>Since the lost blood is replaced with a
suitable fluid, the diluted blood flows more
easily, even in small vessels. As a result more
oxygen is released to the tissue.
8. Uses of plasma expanders
>Used in condition where blood or plasma has
been lost or has moved to extravascular
compartments eg., in burns, severe trauma ,
extensive tissue damage.
>Can be used in temporary measures in case
of blood loss but do not have oxygen carrying
capacity[Crystalloids]
9. Examples of Expanders:-
1:-Human Albumin
>It is obtained from blood plasma.
>It can be used without regard to patient’s blood
group and doesn’t interfere with coagulation.
>It is free of risk of transmission of hepatitis
because the preparation is heat treated.
10. >Crystalloids solution must be infused correctly for
optimal benefits .
>It has been used in acute liver failure , dialysis.
>It is comparatively expensive .
Available product :-
>Albudac , albupan 50 or 100 ml
>Albumed 5% , 20% infusion [100ml]
11. 2:-Dextran
>It is highly branched polysaccharide molecule
obtained from sugar beat.
>It is produced by using the bacterial enzyme
dextran sucrase from the bacteria [Leuconostoc
mesenteroides] which grows in sucrose medium.
>Most commonly used plasma expanders and is
available in two forms.
I) Dextran 70
II) Dextran 40
12. I) Dextran 70
>It is commonly used preparation .
>It Expands plasma volume for nearly 24 hr.
>Excreted slowly from glomerular filtration .
>It is a good for plasma expander but have some
problems such as :-
a)It interfere with blood coagulation and prolong
bleeding time .
b)Some polysaccharide may react with dextran and
triggers anaphylactic reaction like itching .
13. II) Dextran 40
>It is 10% solution in Dextrose or saline .
>It acts more rapidly than dextrose 70.
>It reduces blood viscosity.
>Dextran 40 is cheaper and stored for 10 years.
It also have some problems:-
a)It is excreted through renal tubules and
occasionally may produce acute renal failure.
b)Dextran 40 doesn’t provide necessary electrolyte
and can cause electrolyte disturbance.
14. III) Poly vinyl pyrrolidine (pvp)
>It is a synthetic polymer and used in 3.5%.
>PVP was blood plasma expander for trauma victims
from 1950s.
>It causes histamine release.
>It binds with Penicillin and Insulin.
>It is excreted by kidney and small amount into
bile.
>It is less commonly used in plasma expanders.
15. Other commonly used Crystalloids :-
I)Normal Saline (Isotonic)
It consist of 0.9% Nacl. It is frequently used in
patients where they cannot take fluids orally.
II)Dextrose solution .
It consist of 5% Dextrose solution. It provides energy
to the body parts i.e., upto 170kcal/lit.